A new oral drug from Poolbeg Pharma is set to be tested at six NHS hospitals to prevent cytokine release syndrome, a dangerous immune reaction in cancer patients. By reducing the risk of this side-effect, the treatment could allow patients to receive care in local hospitals rather than specialist centres, potentially increasing access to therapy across the UK.